Program
Microbial Collagenase
Also written as “EN3835”, “Santyl” and “AA4500”.
Its studies are mostly in Cellulite · Penile Induration · Dupuytren Contracture · Diabetic Foot · Bursitis, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keenova Therapeutics | 382 open or running | phase 4since Dec 17, 2011 | Sep 11, 2007 | Dec 2027phase 3 · NCT07759362 |
| Advance Biofactures | 10 open or running | phase 1since Aug 22, 2016 | Aug 22, 2016 | none ahead |
| Asahi Kasei Therapeutics | 10 open or running | phase 3since Apr 27, 2012 | Apr 27, 2012 | none ahead |
| Luxurgery | 10 open or running | phase 4since Mar 24, 2022 | Mar 24, 2022 | none ahead |
| Manhattan Medical Research Practice, PLLC | 10 open or running | phase 4since Nov 30, 2018 | Nov 30, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 28 studies since Sep 11, 2007.
- Nov 30, 2018Manhattan Medical Research Practice, PLLC's first study: phase 4 study in Penile IndurationNew to Manhattan Medical Research Practice, PLLCManhattan Medical Research Practice, PLLC · NCT03767452 · 20 enrolled · United States
- Nov 18, 2019Phase 3 study in CelluliteKeenova Therapeutics · NCT04170296 · 153 enrolled · United States, Puerto Rico
- Dec 11, 2019Phase 2 study in CelluliteKeenova Therapeutics · NCT04209530 · 7 enrolled · United States
- Jan 2, 2020Phase 2 study in Characteristics of Subcutaneous TissueKeenova Therapeutics · NCT04236635 · 10 enrolled · United States
- Jul 29, 2020Phase 2 study in BursitisKeenova Therapeutics · NCT04496167 · 198 enrolled · United States
- Oct 2, 2020Phase 2 study in CelluliteKeenova Therapeutics · NCT04580303 · 35 enrolled · United States
- Nov 29, 2021Phase 2 study in Fibromatosis, PlantarKeenova Therapeutics · NCT05152173 · 176 enrolled · United States
- Feb 15, 2022Phase 3 study in Fibromatosis, PlantarKeenova Therapeutics · NCT05254457 · 145 enrolled · United States
- Mar 24, 2022Luxurgery's first study: phase 4 study in CelluliteNew to LuxurgeryLuxurgery · NCT05309525 · 17 enrolled · United States
- Jun 9, 2022Phase 2 study in CelluliteKeenova Therapeutics · NCT05419505 · 91 enrolled · United States
- Nov 21, 2023Phase 3 study in Fibromatosis, PlantarKeenova Therapeutics · NCT06151197 · 436 enrolled · United States, Puerto Rico
- Dec 5, 2023Phase 2 study in Fasciitis, PlantarKeenova Therapeutics · NCT06169319 · 231 enrolled · United States
- Aug 7, 2026Phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07759362 · 554 planned · United States
- Sep 23, 2026Phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07846280 · 470 planned · United States
Ahead
- Dec 2027Primary completion: phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07759362
- Dec 2028Primary completion: phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07846280
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07846280Flexible Hammertoe · United States | 3 | Recruiting | Keenova Therapeutics | Dec 2028 | 470 |
| NCT07759362Flexible Hammertoe · United States | 3 | Recruiting | Keenova Therapeutics | Dec 2027 | 554 |
| NCT06169319Fasciitis, Plantar · United States | 2 | Completed | Keenova Therapeutics | Sep 30, 2024 | 231 |
| NCT06151197Fibromatosis, Plantar · United States, Puerto Rico | 3 | Completed | Keenova Therapeutics | Jun 9, 2026 | 436 |
| NCT05419505Cellulite · United States | 2 | Completed | Keenova Therapeutics | Jan 3, 2023 | 91 |
| NCT05309525Cellulite · United States | 4 | Completed | Luxurgery | Sep 1, 2022 | 17 |
| NCT05254457Fibromatosis, Plantar · United States | 3 | Completed | Keenova Therapeutics | Mar 21, 2024 | 145 |
| NCT05152173Fibromatosis, Plantar · United States | 2 | Completed | Keenova Therapeutics | Jan 10, 2023 | 176 |
| NCT04580303Cellulite · United States | 2 | Completed | Keenova Therapeutics | Aug 30, 2021 | 35 |
| NCT04496167Bursitis · United States | 2 | Completed | Keenova Therapeutics | Apr 14, 2022 | 198 |
| NCT04236635Characteristics of Subcutaneous Tissue · United States | 2 | Completed | Keenova Therapeutics | Sep 23, 2020 | 10 |
| NCT04209530Cellulite · United States | 2 | Terminated | Keenova Therapeutics | Jul 23, 2020 | 7 |
| NCT04170296Cellulite · United States, Puerto Rico | 3 | Completed | Keenova Therapeutics | Oct 6, 2020 | 153 |
| NCT03767452Penile Induration · United States | 4 | UNKNOWN | Manhattan Medical Research Practice, PLLC | Dec 2019 | 20 |
| NCT03675685Cellulite · United States | 1 | Completed | Keenova Therapeutics | Nov 1, 2018 | 12 |
| NCT03632993Cellulite · United States | 2 | Completed | Keenova Therapeutics | Jan 24, 2019 | 64 |
| NCT03526549Cellulite · United States | 3 | Completed | Keenova Therapeutics | Oct 8, 2021 | 483 |
| NCT03446781Cellulite · United States | 3 | Completed | Keenova Therapeutics | Sep 26, 2018 | 422 |
| NCT03428750Cellulite · United States | 3 | Completed | Keenova Therapeutics | Sep 26, 2018 | 423 |
| NCT03329989Cellulite · United States | 2 | Completed | Keenova Therapeutics | Sep 5, 2018 | 158 |
| NCT02942160Cellulite · United States | 2 | Completed | Keenova Therapeutics | Jun 14, 2018 | 259 |
| NCT02889848Leiomyoma · United States | 1 | Completed | Advance Biofactures | Oct 5, 2018 | 15 |
| NCT02724644Cellulite · United States | 2 | Completed | Keenova Therapeutics | Sep 2016 | 375 |
| NCT02193828Dupuytren Contracture · United States, Australia | 2 | Completed | Keenova Therapeutics | Dec 2014 | 76 |
| NCT02006719Bursitis · United States, Australia | 2 | Completed | Keenova Therapeutics | Dec 2014 | 322 |
| NCT01987986Cellulite · United States | 2 | Completed | Keenova Therapeutics | Aug 2014 | 150 |
| NCT01685437Penile Induration | 3 | Completed | Keenova Therapeutics | Dec 2013 | 189 |
| NCT01588353Dupuytren Contracture · Japan | 3 | Completed | Asahi Kasei Therapeutics | Jan 2014 | 104 |
| NCT01518907Cellulite · United States | 1 | Completed | Keenova Therapeutics | Dec 2012 | 99 |
| NCT01498640Dupuytren Contracture · United States, Australia, Sweden and more | 4 | Completed | Keenova Therapeutics | Oct 2013 | 52 |
| NCT01483963Bursitis · United States | 2 | Completed | Keenova Therapeutics | Feb 2013 | 50 |
| NCT01430169Penile Induration · United States | 2 | Completed | Keenova Therapeutics | Nov 2011 | 20 |
| NCT01407068Dupuytren Contracture · United States, Australia | 3 | Completed | Keenova Therapeutics | Feb 2012 | 60 |
| NCT01243411Penile Induration · United States, Denmark, France and more | 3 | Completed | Keenova Therapeutics | Aug 2012 | 348 |
| NCT01221623Penile Induration · United States, Australia | 3 | Completed | Keenova Therapeutics | Mar 2012 | 418 |
| NCT01221597Penile Induration · United States, Australia | 3 | Completed | Keenova Therapeutics | Apr 2012 | 418 |
| NCT00755222Penile Induration · United States | 2 | Completed | Keenova Therapeutics | Dec 2009 | 147 |
| NCT00533273Advanced Dupuytren's Disease · Australia | 3 | Completed | Keenova Therapeutics | Sep 2008 | 66 |
| NCT00528931Dupuytren Contracture · United States | 1 | Completed | Keenova Therapeutics | Dec 2007 | 16 |
| NCT00528840Advanced Dupuytren's Disease · United States | 3 | Completed | Keenova Therapeutics | Oct 2008 | 201 |
| NCT00528606Dupuytren Contracture · United States | 3 | Completed | Keenova Therapeutics | Apr 2008 | 308 |
| NCT00528424Advanced Dupuytren's Disease · United States | 3 | Completed | Keenova Therapeutics | Nov 2008 | 286 |
How it is read
Names in the registry
- “EN3835”, 9 entries
- “Santyl”, 7 entries
- “AA4500”, 7 entries
- “collagenase clostridium histolyticum”, 5 entries
- “Collagenase Clostridium Histolyticum”, 5 entries
Conditions, from the studies’ own filings
- Cellulite, 15 studies
- Penile Induration, 7 studies
- Dupuytren Contracture, 6 studies
- Diabetic Foot, 5 studies
- Bursitis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.